Skip to main
SRDX
SRDX logo

Surmodics (SRDX) Stock Forecast & Price Target

Surmodics (SRDX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 14%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Surmodics Inc. reported a revenue increase of 17% in F4Q24, excluding SurVeil license fees, marking a significant improvement compared to the previous quarter's 9% growth. The company's revenue estimates for FY25 and FY26 have been raised, projecting revenues of $137.6 million and $148.8 million respectively, which indicates strong growth expectations. Additionally, the successful distribution of the SurVeil drug-coated balloon by Abbott is anticipated to contribute substantially to revenue, suggesting a promising outlook for the company’s financial performance.

Bears say

Surmodics Inc's first-quarter revenue for fiscal 2025 fell short of consensus estimates, marked by a significant slowdown in revenue growth, which contracted by 2% compared to a growth of 17% in the previous quarter, primarily due to a decline in SurVeil sales. The company's revenue in this quarter was reported at $29.9 million, reflecting a 3% decrease when excluding SurVeil license fee revenue, with revised fiscal year 2025 and 2026 revenue estimates lowered to account for anticipated continued declines in SurVeil product sales. Furthermore, expectations indicate a $5 million revenue decline for SurVeil DCB products in fiscal 2025, as replenishment orders are failing to compensate for prior stocking orders in fiscal 2024.

Surmodics (SRDX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surmodics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surmodics (SRDX) Forecast

Analysts have given Surmodics (SRDX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Surmodics (SRDX) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surmodics (SRDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.